Nicholas Hornstein, Assistant Professor at Northwell Health, shared a post on LinkedIn:
“Drug development is supposed to be linear.
Build the drug – use the drug – resistance shows up – then figure out what to do next.
And not what Revolution Medicines is doing.
At AACR26, they disclosed RM-055, which honestly, is a unique concept.
Before DaraxONRASib is even fully in the world, they’re building around resistance.
How it works:
- Most mutant RAS proteins are relatively resistant to GAP-mediated hydrolysis
- That helps keep RAS in the active state
- They’ve found a way to enhance that hydrolysis with RM-055
RM-055 can:
- restore hydrolysis in mutant RAS
- flatten daraxonrasib-resistant models
- generate activity even in RAS-amplified settings
That’s a very smart way to think about this space.
Not just ‘here’s our inhibitor.’
More like: we already know resistance to our drug is coming, so let’s start building now.
That’s how we cure cancer, not more me-toos (if I hear about another new PD1 program, I’m going to cry).”
Other articles featuring Nicholas Hornstein on OncoDaily.
Backbiome is an advanced daily wellness supplement formulated to help support spinal comfort, reduce feelings of built-up tension, and promote freer, smoother movement throughout backbiome everyday life.